Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia

Malignant pleural mesothelioma (MPM) is the most common primary pleural tumor and aggressive neoplasm that arises from the mesothelium of the pleura. The prognosis is poor with a median survival of 9.2 to 11.2 months [1 –3], although a better prognosis with a median survival of 5 years is reported for MPM with germline BAP1 mutations [4,5]. In the diagnosis of MPM, it is important to differentiate it from reactive mesothelial hyperplasia (RMH). RMH is a benign process, but sometimes resembles MPM histologically a nd cytologically [6–8].

Source: Lung Cancer - February 27, 2019 Category: Cancer & Oncology Authors: Masayo Yoshimura, Yoshiaki Kinoshita, Makoto Hamasaki, Shinji Matsumoto, Tomoyuki Hida, Yoshinao Oda, Akinori Iwasaki, Kazuki Nabeshima Source Type: research